Literature DB >> 15816899

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.

Giuseppe Remuzzi1, Piero Ruggenenti, Michele Colledan, Bruno Gridelli, Alessandro Bertani, Paola Bettinaglio, Sara Bucchioni, Aurelio Sonzogni, Ezio Bonanomi, Valter Sonzogni, Jeffrey L Platt, Norberto Perico, Marina Noris.   

Abstract

Factor H-associated hemolytic uremic syndrome (HUS) is a genetic form of thrombotic microangiopathy characterized by deficient factor H (HF-1) levels/activity and uncontrolled complement activation. The disorder mostly leads to end-stage renal disease and often recurs after kidney transplantation. We previously demonstrated that in a child with HF-1-associated HUS a simultaneous kidney and liver transplantation restored the defective HF-1 with no recurrence of the disease in the transplanted kidney. Here we describe a second childhood case of HF-1-associated HUS treated by combined kidney and liver transplant and complicated by a fatal, primary non-function of the liver graft. Graft hypoperfusion during surgery triggered ischemia/reperfusion changes and complement activation. Conceivably, as a result of defective complement regulatory potential, massive shedding of vascular heparan sulfates was documented in the transplanted liver. This might have impaired the physiological thromboresistance of vascular endothelium ending with widespread microvascular thrombosis and infarction. This case indicates that more fundamental research is needed before combined liver and kidney transplant is considered an option for children with HF-1-associated HUS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816899     DOI: 10.1111/j.1600-6143.2005.00783.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  38 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 2.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

3.  Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.

Authors:  Micah R Chan; Christie P Thomas; Jose R Torrealba; Arjang Djamali; Luis A Fernandez; Carla J Nishimura; Richard J H Smith; Millie D Samaniego
Journal:  Am J Kidney Dis       Date:  2008-09-21       Impact factor: 8.860

4.  Complement factor H-deficient mice develop spontaneous hepatic tumors.

Authors:  Jennifer Laskowski; Brandon Renner; Matthew C Pickering; Natalie J Serkova; Peter M Smith-Jones; Eric T Clambey; Raphael A Nemenoff; Joshua M Thurman
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

5.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 6.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

7.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 9.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

10.  Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

Authors:  Jeffrey Saland
Journal:  Pediatr Nephrol       Date:  2013-12-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.